ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) 20 February...

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
20 February 2014

DR. BRADLEY J. MONK TO JOIN PRIMA BIOMED’S CLINICAL ADVISORY BOARD

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, “the Company”) announced today that Bradley J. Monk, MD, an esteemed clinical researcher and practicing gynecological oncologist, has joined Prima’s Clinical Advisory Board to advise the Company’s development of CVac™ for the treatment of epithelial ovarian cancer.

Dr. Monk is an active member of steering committees (SC) for the National Cancer Institute (NCI) and Gynecological Oncology Group (GOG). He has also chaired multiple steering committees for clinical trials in ovarian cancer. For example, he was the chair of OVA301 that led to the approval of trabectedin in many countries. He also chaired Amgen’s Global Steering Committee for the development of AMG 386/trebananib to treat ovarian cancer. Currently, he is the SC chair for Array’s MEK162 ovarian cancer program. Finally, he has also served as a Principal Investigator on dozens of industry- and NCI-sponsored ovarian cancer clinical trials.
Dr. Monk’s current appointments include Professor in the Department of Obstetrics and Gynecology at the University of Arizona College of Medicine, Professor at Creighton University School of Medicine, and Director of the Division of Gynecologic Oncology at St. Joseph’s Hospital and Medical Center in Phoenix Arizona.

Matthew Lehman, Prima’s CEO, on Dr. Monk’s appointment: “I am delighted that Dr. Monk has chosen to join our Clinical Advisory Board. He is one of the most recognized and experienced researchers in ovarian cancer today and I believe he will be able to contribute significantly to
our development strategy.”

Dr. Monk, on joining Prima BioMed’s Clinical Advisory Board, “The scientific community is confident that immunotherapy will play an important role in the future treatment of ovarian cancer. I am excited to be a part of the CVac clinical trial program and help guide the product through development.”
Dr. Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncologists, the
American Society of Clinical Oncology and the American Association for Cancer Research and other professional organizations. He is a current member of the editorial boards of several journals, including Gynecologic Oncology and Clinical Ovarian Cancer, and a reviewer for journals including Clinical Cancer Research, Obstetrics and Gynecology, Cancer and Journal of Clinical Oncology.

Among other numerous accolades, Dr. Monk received the 2013 Ernst Wertheim Award from the Austrian Association of Gynecologic Oncology, has been named a “Top Doctor” by PHOENIX Magazine the past two years, and has been named a “Best Doctor in America” by Best Doctors, Inc. three times in recent years.

ENDS